New Vaccines for Chronic Respiratory Patients
Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations...
Gespeichert in:
Veröffentlicht in: | Archivos de bronconeumología (English ed.) 2024-09, Vol.60 (9), p.565-575 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 575 |
---|---|
container_issue | 9 |
container_start_page | 565 |
container_title | Archivos de bronconeumología (English ed.) |
container_volume | 60 |
creator | Mallah, Narmeen Urbieta, Ana Dacosta Rivero-Calle, Irene Gonzalez-Barcala, Francisco-Javier Bigoni, Tommaso Papi, Alberto Martinón-Torres, Federico |
description | Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients. |
doi_str_mv | 10.1016/j.arbres.2024.05.026 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3068749889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030028962400190X</els_id><sourcerecordid>3068749889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2726-681e2ccec7d154659623ec5edea8d606e463ff7bf4995cc58c09bf6026ac959b3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwBwhlySZh7MSOvUFCFS8JAULA1nImE-GqTYqdgvr3pGphyWo2587VPYydcsg4cHUxy1yoAsVMgCgykBkItcfGXJYmFVyYfTaGHCAV2qgRO4pxBiBkXohDNsq1LpXheszSR_pO3h2ibykmTReS6UfoWo_JC8WlD67vwjp5dr2nto_H7KBx80gnuzthbzfXr9O79OHp9n569ZCiKIVKleYkEAnLmstCSaNETiipJqdrBYoKlTdNWTWFMRJRagRTNWoY4NBIU-UTdr79uwzd54pibxc-Is3nrqVuFW0OSpeF0doMaLFFMXQxBmrsMviFC2vLwW5E2ZndirIbURakHXqG2NmuYVUtqP4L_ZoZgMstQMPOL0_BRhwcINU-EPa27vz_DT-3b3p9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3068749889</pqid></control><display><type>article</type><title>New Vaccines for Chronic Respiratory Patients</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Mallah, Narmeen ; Urbieta, Ana Dacosta ; Rivero-Calle, Irene ; Gonzalez-Barcala, Francisco-Javier ; Bigoni, Tommaso ; Papi, Alberto ; Martinón-Torres, Federico</creator><creatorcontrib>Mallah, Narmeen ; Urbieta, Ana Dacosta ; Rivero-Calle, Irene ; Gonzalez-Barcala, Francisco-Javier ; Bigoni, Tommaso ; Papi, Alberto ; Martinón-Torres, Federico</creatorcontrib><description>Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.</description><identifier>ISSN: 0300-2896</identifier><identifier>ISSN: 1579-2129</identifier><identifier>EISSN: 1579-2129</identifier><identifier>DOI: 10.1016/j.arbres.2024.05.026</identifier><identifier>PMID: 38876918</identifier><language>eng</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Chronic respiratory diseases ; Influenza ; Monoclonal antibody ; Pertussis ; Pneumococcal disease vaccine ; Respiratory syncytial virus ; SARS-CoV-2 ; Vaccine</subject><ispartof>Archivos de bronconeumología (English ed.), 2024-09, Vol.60 (9), p.565-575</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier España, S.L.U. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2726-681e2ccec7d154659623ec5edea8d606e463ff7bf4995cc58c09bf6026ac959b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.arbres.2024.05.026$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38876918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mallah, Narmeen</creatorcontrib><creatorcontrib>Urbieta, Ana Dacosta</creatorcontrib><creatorcontrib>Rivero-Calle, Irene</creatorcontrib><creatorcontrib>Gonzalez-Barcala, Francisco-Javier</creatorcontrib><creatorcontrib>Bigoni, Tommaso</creatorcontrib><creatorcontrib>Papi, Alberto</creatorcontrib><creatorcontrib>Martinón-Torres, Federico</creatorcontrib><title>New Vaccines for Chronic Respiratory Patients</title><title>Archivos de bronconeumología (English ed.)</title><addtitle>Arch Bronconeumol</addtitle><description>Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.</description><subject>Chronic respiratory diseases</subject><subject>Influenza</subject><subject>Monoclonal antibody</subject><subject>Pertussis</subject><subject>Pneumococcal disease vaccine</subject><subject>Respiratory syncytial virus</subject><subject>SARS-CoV-2</subject><subject>Vaccine</subject><issn>0300-2896</issn><issn>1579-2129</issn><issn>1579-2129</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EoqXwBwhlySZh7MSOvUFCFS8JAULA1nImE-GqTYqdgvr3pGphyWo2587VPYydcsg4cHUxy1yoAsVMgCgykBkItcfGXJYmFVyYfTaGHCAV2qgRO4pxBiBkXohDNsq1LpXheszSR_pO3h2ibykmTReS6UfoWo_JC8WlD67vwjp5dr2nto_H7KBx80gnuzthbzfXr9O79OHp9n569ZCiKIVKleYkEAnLmstCSaNETiipJqdrBYoKlTdNWTWFMRJRagRTNWoY4NBIU-UTdr79uwzd54pibxc-Is3nrqVuFW0OSpeF0doMaLFFMXQxBmrsMviFC2vLwW5E2ZndirIbURakHXqG2NmuYVUtqP4L_ZoZgMstQMPOL0_BRhwcINU-EPa27vz_DT-3b3p9</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Mallah, Narmeen</creator><creator>Urbieta, Ana Dacosta</creator><creator>Rivero-Calle, Irene</creator><creator>Gonzalez-Barcala, Francisco-Javier</creator><creator>Bigoni, Tommaso</creator><creator>Papi, Alberto</creator><creator>Martinón-Torres, Federico</creator><general>Elsevier España, S.L.U</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240901</creationdate><title>New Vaccines for Chronic Respiratory Patients</title><author>Mallah, Narmeen ; Urbieta, Ana Dacosta ; Rivero-Calle, Irene ; Gonzalez-Barcala, Francisco-Javier ; Bigoni, Tommaso ; Papi, Alberto ; Martinón-Torres, Federico</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2726-681e2ccec7d154659623ec5edea8d606e463ff7bf4995cc58c09bf6026ac959b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chronic respiratory diseases</topic><topic>Influenza</topic><topic>Monoclonal antibody</topic><topic>Pertussis</topic><topic>Pneumococcal disease vaccine</topic><topic>Respiratory syncytial virus</topic><topic>SARS-CoV-2</topic><topic>Vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mallah, Narmeen</creatorcontrib><creatorcontrib>Urbieta, Ana Dacosta</creatorcontrib><creatorcontrib>Rivero-Calle, Irene</creatorcontrib><creatorcontrib>Gonzalez-Barcala, Francisco-Javier</creatorcontrib><creatorcontrib>Bigoni, Tommaso</creatorcontrib><creatorcontrib>Papi, Alberto</creatorcontrib><creatorcontrib>Martinón-Torres, Federico</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archivos de bronconeumología (English ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mallah, Narmeen</au><au>Urbieta, Ana Dacosta</au><au>Rivero-Calle, Irene</au><au>Gonzalez-Barcala, Francisco-Javier</au><au>Bigoni, Tommaso</au><au>Papi, Alberto</au><au>Martinón-Torres, Federico</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Vaccines for Chronic Respiratory Patients</atitle><jtitle>Archivos de bronconeumología (English ed.)</jtitle><addtitle>Arch Bronconeumol</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>60</volume><issue>9</issue><spage>565</spage><epage>575</epage><pages>565-575</pages><issn>0300-2896</issn><issn>1579-2129</issn><eissn>1579-2129</eissn><abstract>Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.</abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>38876918</pmid><doi>10.1016/j.arbres.2024.05.026</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0300-2896 |
ispartof | Archivos de bronconeumología (English ed.), 2024-09, Vol.60 (9), p.565-575 |
issn | 0300-2896 1579-2129 1579-2129 |
language | eng |
recordid | cdi_proquest_miscellaneous_3068749889 |
source | Elsevier ScienceDirect Journals Complete |
subjects | Chronic respiratory diseases Influenza Monoclonal antibody Pertussis Pneumococcal disease vaccine Respiratory syncytial virus SARS-CoV-2 Vaccine |
title | New Vaccines for Chronic Respiratory Patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T14%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Vaccines%20for%20Chronic%20Respiratory%20Patients&rft.jtitle=Archivos%20de%20bronconeumologi%CC%81a%20(English%20ed.)&rft.au=Mallah,%20Narmeen&rft.date=2024-09-01&rft.volume=60&rft.issue=9&rft.spage=565&rft.epage=575&rft.pages=565-575&rft.issn=0300-2896&rft.eissn=1579-2129&rft_id=info:doi/10.1016/j.arbres.2024.05.026&rft_dat=%3Cproquest_cross%3E3068749889%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3068749889&rft_id=info:pmid/38876918&rft_els_id=S030028962400190X&rfr_iscdi=true |